{"Symbol": "ABUS", "AssetType": "Common Stock", "Name": "Arbutus Biopharma Corp", "Description": "Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.", "CIK": "1447028", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "701 VETERANS CIRCLE, WARMINSTER, PA, UNITED STATES, 18974", "OfficialSite": "https://www.arbutusbio.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "765450000", "EBITDA": "-30670000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.403", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.23", "RevenuePerShareTTM": "0.076", "ProfitMargin": "-2.894", "OperatingMarginTTM": "-15.68", "ReturnOnAssetsTTM": "-0.165", "ReturnOnEquityTTM": "-0.459", "RevenueTTM": "14606000", "GrossProfitTTM": "-14439000", "DilutedEPSTTM": "-0.23", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.605", "AnalystTargetPrice": "5.78", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "2", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "52.41", "PriceToBookRatio": "9.91", "EVToRevenue": "46.19", "EVToEBITDA": "-5.64", "Beta": "0.717", "52WeekHigh": "5.1", "52WeekLow": "2.705", "50DayMovingAverage": "4.423", "200DayMovingAverage": "3.963", "SharesOutstanding": "192324000", "SharesFloat": "124530000", "PercentInsiders": "21.803", "PercentInstitutions": "65.287", "DividendDate": "None", "ExDividendDate": "None"}